UPDATED May 03, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
GTHX | US$4.49 | 12.5% | 45.8% | US$232.2m | US$8.50 | PS2.8x | E41.0% | n/a | Pharmaceuticals & Biotech | ||
ACTD | US$7.79 | -24.2% | -21.2% | US$303.0m | US$17.00 | PE-25.3x | E85.2% | n/a | Diversified Financials | ||
AZ | US$0.42 | 7.0% | -66.4% | US$21.0m | US$18.00 | PS1.9x | E75.4% | n/a | Capital Goods | ||
LICY | US$0.71 | 4.5% | -85.8% | US$126.3m | n/a | PS6.9x | E60.1% | n/a | Commercial Services | ||
SONM | US$0.54 | 10.7% | -43.1% | US$23.5m | US$2.00 | PB1x | E139.9% | n/a | Tech | ||
ZYNE | US$1.30 | 4.0% | 96.1% | US$65.6m | US$1.26 | PB2.3x | E67.2% | n/a | Pharmaceuticals & Biotech | ||
ZVRA | US$4.81 | 6.4% | -2.0% | US$198.8m | US$19.00 | PS7.3x | E63.6% | n/a | Pharmaceuticals & Biotech | ||
CKPT | US$1.58 | 10.5% | -47.7% | US$52.8m | US$17.25 | PS547.4x | E88.1% | n/a | Pharmaceuticals & Biotech | ||
IREN | US$4.73 | -6.9% | 26.8% | US$644.8m | US$11.00 | PS5.4x | E110.2% | n/a | Software | ||
GMED | US$51.95 | 2.8% | -11.1% | US$6.8b | US$65.31 | PE57.1x | E31.3% | n/a | Healthcare | ||
AQMS | US$0.47 | -6.0% | -55.4% | US$52.6m | US$3.00 | PS2118.7x | E63.4% | n/a | Commercial Services | ||
MVST | US$0.38 | -6.4% | -66.8% | US$126.6m | US$4.50 | PB0.2x | E44.4% | n/a | Capital Goods | ||
XELB | US$0.73 | 6.9% | 31.8% | US$18.3m | US$3.00 | PB0.3x | E114.9% | n/a | Retail | ||
PGEN | US$1.42 | 0.7% | 16.4% | US$348.5m | US$9.00 | PS56.8x | E55.5% | n/a | Pharmaceuticals & Biotech | ||
AMPG | US$2.26 | -1.3% | -30.5% | US$21.4m | US$9.00 | PS1.4x | E107.0% | n/a | Tech | ||
SCPH | US$4.66 | 3.8% | -58.3% | US$168.0m | US$19.50 | PS12.4x | E59.8% | n/a | Pharmaceuticals & Biotech | ||
PESI | US$11.70 | -2.9% | 31.5% | US$174.2m | US$19.00 | PE174.2x | E133.4% | n/a | Commercial Services | ||
OCUP | US$1.99 | 23.6% | -67.8% | US$47.4m | US$19.50 | PS2.7x | E9.5% | n/a | Pharmaceuticals & Biotech | ||
PTGX | US$26.09 | 3.7% | 5.2% | US$1.5b | US$43.00 | PS25.5x | E50.0% | n/a | Pharmaceuticals & Biotech | ||
DTST | US$5.08 | -1.0% | 183.8% | US$35.1m | US$9.00 | PE92.1x | E65.4% | n/a | Software | ||
VRCA | US$7.26 | 5.7% | 10.8% | US$286.8m | US$13.60 | PS60.1x | E61.6% | n/a | Pharmaceuticals & Biotech | ||
APLT | US$4.76 | 11.2% | 201.3% | US$517.5m | US$11.60 | PS54.4x | E81.9% | n/a | Pharmaceuticals & Biotech | ||
ALIM | US$3.65 | 4.6% | 92.1% | US$182.2m | US$8.00 | PS2.4x | E58.0% | n/a | Pharmaceuticals & Biotech | ||
AUNA | US$6.49 | -8.1% | n/a | US$499.7m | US$16.05 | PB1.2x | E45.4% | n/a | Healthcare |